Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Seres Therapeutics, Inc. filings document the disclosure record of a Nasdaq-listed biotechnology company focused on live biotherapeutic and microbiome-based therapeutic programs. Its Form 8-K reports furnish quarterly and annual financial results, operational updates, Regulation FD corporate presentations, and material-event disclosures involving pipeline priorities, clinical and regulatory matters, capital allocation, cost-reduction actions, and financing or partnership activity.
The company’s proxy materials cover annual meeting mechanics, stockholder voting, board governance, executive compensation, and equity-award information. SEC filings also identify Seres’ common stock registered under the Exchange Act and traded on the Nasdaq Global Select Market under the symbol MCRB.
Seres Therapeutics, Inc. (MCRB) executive Brady Kelly, EVP and Chief Operating Officer, reported equity transactions involving company stock. On August 15, 2026, a total of 181 shares of Common Stock were acquired upon the vesting and settlement of 181 Restricted Stock Units, each RSU representing one share of common stock. On August 17, 2026, Kelly then sold 64 shares of Common Stock at $4.55 per share. According to the disclosure, the sale was effected under a Rule 10b5-1 trading plan adopted on November 26, 2025, with the stated intent to cover taxes related to the RSU vesting.
Seres Therapeutics, Inc. (MCRB) director Eric D. Shaff reported equity award activity and a small share sale. On August 15, 2026, restricted stock units covering 722 shares of common stock vested and settled into common shares. On August 17, 2026, he sold 263 common shares at $4.55 per share pursuant to a pre-arranged Rule 10b5-1 trading instruction solely to cover taxes related to the RSU vesting.
For Seres Therapeutics, Inc. (MCRB), President and Chief Scientific Officer Matthew R. Henn reported equity compensation activity and a small share sale. On August 15, 2026, he exercised and settled 238 restricted stock units into an equal number of common shares, stemming from RSU grants with vesting schedules described in the footnotes. On August 17, 2026, he then sold 81 common shares at $4.55 per share in an open-market transaction executed under a Rule 10b5-1 trading plan adopted on April 13, 2023, solely to cover taxes related to the RSU vesting.
Seres Therapeutics, Inc. (MCRB) reported insider equity activity by EVP and Chief Legal Officer Thomas DesRosier. On August 15, 2026, a total of 245 shares of common stock were acquired upon settlement of restricted stock units, with two RSU awards of 133 and 112 units each converting into common shares, where each unit represents one share and has no expiration date. On August 17, 2026, 82 shares of common stock were sold at $4.55 per share in an open-market transaction made under a Rule 10b5-1 trading plan adopted on March 2, 2023, described as intended solely to cover taxes related to the RSU vesting.
Seres Therapeutics, Inc. has filed a shelf registration to offer and sell up to $300,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time, using supplements for specific terms. A related sales agreement with TD Securities (USA) LLC (TD Cowen) establishes an at-the-market program for up to $100,000,000 of common stock, with TD Cowen earning up to 3.0% of gross proceeds as sales agent. The company is a clinical-stage microbiome-focused business with a pipeline including SER-155, SER-603, SER-428 and SER-147. Net proceeds from offerings are expected to fund development of product candidates and other general corporate and working capital purposes. Under General Instruction I.B.6, sales in any 12‑month period are limited to one‑third of the $63,154,255.12 public float, and investors are cautioned about potential dilution and other risks described in incorporated risk factors.
Seres Therapeutics reported Q2 2026 results with grant revenue of $736 thousand and net income of $4,581 thousand, compared with a loss a year earlier. Profitability was driven by a $25,000 thousand gain from amending its VOWST sale agreement with Nestlé, which replaces large contingent sales milestones with a fixed Milestone Termination Payment.
Core operations remain loss-making, with a Q2 loss from operations of $21,273 thousand and $42,180 thousand for the first half. Cash and cash equivalents were $15,594 thousand at June 30, 2026, and operating activities used $38,754 thousand of cash year to date. Even after including the $25,000 thousand Nestlé payment (half received in July, half expected in October 2026), management disclosed conditions and events that raise substantial doubt about the company’s ability to continue as a going concern and highlighted the need for additional financing or partnerships.
The company continued restructuring, including a workforce reduction of about 30% and lease amendments that reduced its Cambridge footprint but triggered a $5,807 thousand impairment of long-lived assets. Development is focused on live biotherapeutic candidates SER-155, SER-603, SER-428 and SER-147, with encouraging early data for SER-155 in allo-HCT infections and immune checkpoint-related enterocolitis, though further trials depend on securing funding and collaborations.
Seres Therapeutics reported second-quarter 2026 grant revenue of $736,000 and net income of $4.6 million, compared with a $19.9 million loss a year earlier. Results included a $25.0 million gain from the VOWST business sale and $22.0 million of operating expenses, including a $5.8 million impairment.
The company ended June 30, 2026 with $15.6 million in cash and cash equivalents and, together with milestone termination payments from Nestlé, expects to fund operations into the first quarter of 2027. Seres highlighted encouraging SER-155 data in irEC, is evaluating Phase 2 development, pursuing partners and capital, and further reducing facility lease obligations.
Seres Therapeutics, Inc. entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC to reduce facilities costs and primary restoration obligations at 200 Sidney Street in Cambridge. The company will surrender about 21,295 rentable sq ft and retain about 47,341 rentable sq ft, with the remaining lease term shortened from January 13, 2031 to December 31, 2026.
As consideration, Seres will increase a letter of credit by about $2.2 million to a total of about $3.6 million to be applied to rent and operating expenses, pay a deferred termination amount of $3.85 million by January 4, 2027, and issue 103,520 shares of common stock at $4.83 per share (total $500,001.60) under an existing Form S-3 shelf registration. The shares will be freely tradeable when issued; if their issuance-date market value is below $500,000, Seres must pay the landlord the cash difference.
Seres Therapeutics, Inc. is issuing 103,520 shares of common stock to BMR-Sidney Research Campus LLC under a stock issuance agreement tied to the termination of its Sidney Research Campus lease. The shares are priced at $4.83 per share, matching the July 31, 2026 Nasdaq closing price, for a total value of $500,001.60. Seres will not receive any cash proceeds; the stock is being used as part of the payment owed under a lease termination agreement, and no underwriters or selling agents are involved.
As of March 31, 2026, Seres reported net tangible book value of $26.5 million, or $2.76 per share, based on 9,592,326 shares outstanding. After giving effect to this issuance, as adjusted net tangible book value would have been $2.73 per share, a decrease of $0.03 for existing stockholders and an immediate dilution of $2.10 per share to BMR-Sidney relative to the offering price. The company’s shelf registration statement also permits up to $300 million of additional securities offerings in the future.